Get the Daily Brief
Latest Biotech News
Nine‑figure rounds back neuro‑immune and degrader bets: Nilo $101M, Gate $65M
Two financings signaled investor appetite for biologically novel approaches to immune and brain diseases. Nilo Therapeutics launched with $101 million in Series A funding to develop therapies that...
Clinical lab tools roll out: OGT’s ultra‑sensitive MRD panel and automated single‑cell workflows
OGT launched a SureSeq Myeloid MRD Plus NGS panel engineered to detect measurable residual disease (MRD) in AML down to allele fractions as low as 0.01%, coupled with Interpret bioinformatics for...
AMT‑130 slows Huntington's: Uniqure reports 75% disease‑slowing at three years
Uniqure reported three‑year follow‑up from its AMT‑130 program in Huntington’s disease showing a 75% slowing of progression on the cUHDRS (composite Unified Huntington's Disease Rating Scale)...
Novartis’ GanLum clears phase 3 — New tool vs resistant malaria
Novartis reported Phase 3 results showing its ganaplacide‑lumefantrine combination (GanLum) met the trial’s primary endpoint and achieved cure rates that meet World Health Organization thresholds....
FDA unveils plausible‑mechanism route for bespoke gene edits
Top FDA officials outlined a new regulatory approach—often called the “plausible mechanism” pathway—intended to accelerate approvals for highly individualized gene‑editing therapies. In a...
Pig kidney xenograft rejection reversed — Multi‑omics maps immune drivers
A team published in Nature traced immune responses over 61 days after transplanting a genetically engineered pig kidney into a brain‑dead human decedent and identified the cellular drivers of...
Allen Institute launches Brain Knowledge Platform — 34M‑cell atlas with AI
The Allen Institute released the Brain Knowledge Platform (BKP), an open database aggregating and standardizing datasets from more than 34 million brain cells across 22 species and coupling them...
Day One buys Mersana — Emi‑Le ADC moves to new home
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for $129 million upfront with additional contingent payments that lift the deal value to as much as $285 million, centered on...
Korro cuts staff, abandons lead program — Stock tumbles
Korro Bio announced substantial workforce reductions and a strategic pivot after its RNA‑editing lead program failed to meet potency expectations in early testing. The company said it will cut...
Cellarity unveils AI multi‑omics DILI predictor — New toxicology framework
Cellarity published a framework in Nature Communications outlining an integrated multi‑omics and AI approach to predict drug‑induced liver injury (DILI). The company combined transcriptomics,...
Richard Pazdur named CDER director — FDA taps veteran oncology regulator
The FDA appointed Richard Pazdur—longtime head of the agency’s oncology office—to lead the Center for Drug Evaluation and Research (CDER). The move follows recent leadership turbulence and is...
Nilo launches with $101M — Targets neural circuits to reset immunity
Nilo Therapeutics launched with a $101 million Series A to develop therapies that harness neural circuits to restore immune homeostasis. The New York‑based startup—founded by academic leaders in...
Ultra‑mild sequencing fixes methylation test damage — UMBS‑seq published
Researchers introduced an "ultra‑mild" bisulfite sequencing method (UMBS‑seq) published in Nature Communications that reduces DNA strand damage inherent to traditional bisulfite conversion and...
FDA unveils new pathway for personalized rare‑disease therapies
The FDA announced a formal regulatory approach to speed approval of bespoke, patient‑specific therapies for rare and life‑threatening conditions. Agency officials outlined a “plausible mechanism”...
Novartis’ GanLum passes phase 3 — targets artemisinin resistance
Novartis reported that GanLum, a ganaplacide‑lumefantrine combination, met its primary endpoint in a Phase 3 trial across sub‑Saharan Africa, hitting cure rates that exceed the World Health...
Uniqure’s AMT‑130 shows deep, durable slowing in Huntington’s
Uniqure disclosed Phase 1/2 data from its AMT‑130 gene‑therapy program for Huntington disease showing a sustained reduction in disease progression. The intracerebral AAV‑delivered microRNA therapy...
AbbVie to end Calico collaboration — strategic pivot sends layoffs
AbbVie is terminating its long‑running R&D partnership with Alphabet’s Calico Labs after 11 years, internal documents and reporting show, and plans workforce reductions tied to the wind‑down. The...
Nilo launches with $101M to translate neuro‑immune circuits into drugs
Nilo Therapeutics emerged from academic labs with a $101 million Series A to build therapeutics that modulate neural circuits to restore immune homeostasis. Founders include Columbia’s Charles...
Gate Bioscience raises $65M to advance novel small‑molecule degraders
Gate Bioscience closed a $65 million financing to move its proprietary “molecular gate” class of small‑molecule protein degraders toward first‑in‑human studies. The company is developing degraders...
Cellarity publishes AI multi‑omics test to predict drug‑induced liver injury
Cellarity unveiled an integrated multi‑omics and AI framework to predict drug‑induced liver injury (DILI), publishing methods and validation data in Nature Communications. The clinical‑stage...